Alkermes’ incoming CEO outlines urgency to seize the orexin opportunity, challenging rivals including Eli Lilly and Takeda

Alkermes is preparing for a leadership handoff that its incoming CEO, Blair Jackson, characterized as both immediate and consequential. In comments tied to the company’s next phase, Jackson said the coming 12 months may be the most important in Alkermes’ history, as the Massachusetts-based biopharma company looks to compete in an emerging orexin drug market viewed by analysts as potentially multibillion dollars.

The orexin field has been shaped by the search for therapies that directly target orexin indicating, a pathway involved in wakefulness. For patients and payers, the promise is straightforward in concept: drugs built around orexin biology may offer a more targeted way to treat conditions that disrupt normal sleep and wake cycles. Alkermes has been associated with orexin-linked efforts for sleep disorders, including narcolepsy, a disease in which people experience excessive daytime sleepiness and sudden loss of muscle tone.

Against that backdrop, the leadership message is clear. Jackson framed Alkermes’ near-term strategy around accelerating the company’s ability to win in the orexin space, including in relation to established and well-capitalized competitors. The market comparison highlighted in the reporting placed Eli Lilly and Takeda among the names investors are likely to watch, suggesting they are perceived as credible forces in orexin development.

For Alkermes, the stakes are not just scientific, but executional. In the drug development and commercialization cycle, timing can determine whether a company captures prescribing share early or is forced to differentiate later against products already in the clinic. Jackson’s emphasis on the next year implies a focus on milestones that could include late-stage progress, regulatory timing, and commercial readiness, even though the reporting does not spell out which specific steps are guaranteed within the 12-month window.

The orexin category is widely seen as a competitive frontier because it combines high unmet need with the possibility of significant market pull once therapies reach patients. Analysts cited in the reporting described the opportunity as multibillion dollars, which helps explain why several companies are pursuing the space rather than treating it as a niche market.

For Eli Lilly and Takeda, being mentioned in the same breath as Alkermes highlights how the industry treats orexin as a strategic priority. Large pharma companies have the resources to support multiple clinical programs, handle regulatory complexity across jurisdictions, and sustain commercial efforts if products reach launch. That makes it harder for smaller biopharmas to rely only on good science, because they also need the right mix of momentum and partners to move quickly.

One important caveat is what was not disclosed in the reporting. While the comments point to a multibillion-dollar orexin market and identify rivals in Lilly and Takeda, the material provided does not include details on Alkermes’ specific product candidates, timelines for regulatory filings, expected launch dates, or whether the company plans to rely on partnerships, acquisitions, or internal capabilities. Without those specifics, it is not possible to determine which milestones will define the “next 12 months” in practical terms.

What to watch next is whether Alkermes follows up its leadership messaging with concrete updates that connect strategy to measurable development or commercial steps. Investors and clinicians will likely look for clarity on candidate programs tied to orexin mechanisms, the status of late-stage work, and any guidance that narrows the gap between the competitive narrative and operational execution.